Corcept Therapeutics Faces Class Action Lawsuit

Robbins LLP encourages CORT stockholders to contact the firm about their rights

Apr. 4, 2026 at 6:27am

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a calculator, and a gavel arranged on a clean, monochromatic background, symbolizing the corporate legal and financial implications of the class action lawsuit against Corcept Therapeutics.A class action lawsuit alleges Corcept Therapeutics misled investors about its drug development pipeline.San Diego Today

Robbins LLP has filed a class action lawsuit on behalf of all investors who purchased or acquired Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of its drug relacorilant, which is approaching approval.

Why it matters

The class action lawsuit alleges that Corcept Therapeutics made false and misleading statements about the development and approval prospects of its key drug relacorilant. This could have significant financial and legal implications for the company and its shareholders.

The details

The class action lawsuit claims that Corcept Therapeutics failed to disclose material information about the development and approval process for its drug relacorilant, which is a key product in the company's pipeline. The lawsuit alleges that the company made false and misleading statements that inflated the stock price during the class period.

  • The class action lawsuit was filed on behalf of investors who purchased Corcept Therapeutics stock between October 31, 2024 and December 30, 2025.

The players

Corcept Therapeutics Incorporated

A pharmaceutical company focused on the development of its drug relacorilant, which is approaching approval.

Robbins LLP

A law firm that has filed a class action lawsuit on behalf of Corcept Therapeutics shareholders.

Got photos? Submit your photos here. ›

The takeaway

This class action lawsuit highlights the importance of transparency and accurate disclosure from pharmaceutical companies, especially during the critical drug development and approval process. Investors will be closely watching the outcome of this case and its potential impact on Corcept Therapeutics' future.